
Edurne San José-Enériz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/376282/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism. PLoS Computational Biology, 2022, 18, e1009395.	1.5	5
2	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Frontiers in Immunology, 2022, 13, .	2.2	2
3	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Nature Communications, 2021, 12, 421.	5.8	29
4	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multiple Myeloma. Journal of Medicinal Chemistry, 2021, 64, 3392-3426.	2.9	11
5	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research, 2020, 30, 1217-1227.	2.4	35
6	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood, 2020, 136, 199-209.	0.6	76
7	Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603.	3.6	81
8	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nature Medicine, 2019, 25, 1073-1081.	15.2	125
9	HDAC Inhibitors in Acute Myeloid Leukemia. Cancers, 2019, 11, 1794.	1.7	118
10	COBRA methods and metabolic drug targets in cancer. Molecular and Cellular Oncology, 2018, 5, e1389672.	0.3	3
11	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. Journal of Medicinal Chemistry, 2018, 61, 6518-6545.	2.9	36
12	Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. Journal of Medicinal Chemistry, 2018, 61, 6546-6573.	2.9	19
13	Deregulation of <i>linc-PINT</i> in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells. Oncotarget, 2018, 9, 12842-12852.	0.8	43
14	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nature Communications, 2017, 8, 15424.	5.8	109
15	In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer. Scientific Reports, 2017, 7, 14358.	1.6	10
16	An in-silico approach to predict and exploit synthetic lethality in cancer metabolism. Nature Communications, 2017, 8, 459.	5.8	35
17	Dual epigenetic modifiers for cancer therapy. Molecular and Cellular Oncology, 2017, 4, e1342748.	0.3	2
18	Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome. PLoS ONE, 2017, 12, e0190275.	1.1	10

#	Article	IF	CITATIONS
19	Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Research, 2015, 25, 478-487.	2.4	118
20	Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. Blood, 2014, 124, 3532-3532.	0.6	2
21	Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. Epigenomics, 2013, 5, 525-538.	1.0	13
22	Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia, 2012, 26, 1517-1526.	3.3	41
23	Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNFα regulation and proliferation of hematopoietic progenitor cells. Blood, 2012, 119, 3042-3049.	0.6	23
24	Román-Gómez J, Cordeu L, Agirre X, Jiménez-Velasco A, San José-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A, Prosper F. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood. 2007;109(8):3462–3469 Blood, 2012, 120, 3625-3625.	0.6	4
25	Deregulation of <i>FGFR1</i> and <i>CDK6</i> oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the <i>MIR9</i> family. British Journal of Haematology, 2011, 155, 73-83.	1.2	53
26	Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia. PLoS ONE, 2011, 6, e17012.	1.1	52
27	Epigenetic regulation of the nonâ€canonical Wnt pathway in acute myeloid leukemia. Cancer Science, 2010, 101, 425-432.	1.7	43
28	Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2009, 27, 1316-1322.	0.8	131
29	Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. European Journal of Cancer, 2009, 45, 1877-1889.	1.3	76
30	MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Molecular Cancer, 2009, 8, 69.	7.9	101
31	Epigenetic Silencing of the Tumor Suppressor MicroRNA <i>Hsa-miR-124a</i> Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia. Cancer Research, 2009, 69, 4443-4453.	0.4	299
32	Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leukemia Research, 2008, 32, 487-490.	0.4	71
33	Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leukemia Research, 2008, 32, 709-716.	0.4	39
34	Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphiaâ€positive acute lymphoblastic leukemia. Cancer Science, 2008, 99, 1865-1868.	1.7	29
35	<i>BCRâ€ABL1</i> â€induced expression of <i>HSPA8</i> promotes cell survival in chronic myeloid leukaemia. British Journal of Haematology, 2008, 142, 571-582.	1.2	33
36	Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. European Journal of Heart Failure, 2008, 10, 1065-1072.	2.9	119

#	Article	IF	CITATIONS
37	Down-Regulation of <i>hsa-miR-10a</i> in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. Molecular Cancer Research, 2008, 6, 1830-1840.	1.5	208
38	Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood, 2007, 109, 3462-3469.	0.6	153
39	Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica, 2007, 92, 153-162.	1.7	54
40	WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. European Journal of Cancer, 2007, 43, 2736-2746.	1.3	66
41	Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leukemia Research, 2007, 31, 1521-1528.	0.4	60
42	Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. British Journal of Haematology, 2006, 134, 137-144.	1.2	30
43	Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia, 2006, 20, 1445-1447.	3.3	46
44	CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2006, 12, 4845-4850.	3.2	62